Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application

A technology of immune adjuvant and total ginseng saponins, applied in the field of preparation of vaccine immune adjuvants by total ginsenosides or monomeric saponins Rb1, which can solve problems such as stimulation, toxicity, and complex components of propolis, and achieve short and extended validity periods Effect

Inactive Publication Date: 2004-03-10
ZHEJIANG UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, oil-emulsion adjuvants have been widely used in veterinary medicine in my country, but because of local irritation and difficult degradation in the body, many developed countries prohibit their use on food animals.
In order to promote the export of animal products in my country, the use of oil adjuvants will be restricted accordingly
Artificially synthesized muramyl dipeptide (MDP) has a good adjuvant effect, which is still in the research stage
Quil-A (a saponin extracted from Quillaba bark) has a strong adjuvant effect, but it cannot be used clinically because of its toxic effects and local reactions
(2) There are reports of propolis adjuvants in my country, but the composition of propolis is extremely complex and difficult to control the quality. Currently, it is only used in some animal vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application
  • Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] 1) Dissolving total ginsenosides or ginsenoside monomer Rb1 in physiological saline to prepare a solution of total ginsenosides and ginsenoside monomer Rb1. Mix inactivated Staphylococcus aureus and ginsenoside solution to prepare Staphylococcus aureus vaccines containing different adjuvants. Each milliliter of vaccine contains 10 6 Inactivated Staphylococcus aureus.

[0014] 2) Subcutaneously inject guinea pigs with 1 ml of the above vaccine. Two weeks later, the same method was used to inject once more. Before the first injection and 2 weeks after the second injection, blood samples were collected and serum was separated. Serum IgG content was detected by agar diffusion method. Elevated IgG levels indicate an enhanced humoral immune response.

[0015] Minute

Embodiment 2

[0017] 1) Dissolving total ginsenosides or ginsenoside monomer Rb1 in physiological saline at concentrations of 4 mg / ml and 1 mg / ml, respectively. Sterilize the solution through a 0.22 micron filter. Store at room temperature and set aside.

[0018] 2) After mixing 5 ml of commercial inactivated Staphylococcus aureus vaccine (containing aluminum hydroxide adjuvant) and 1 ml of total ginsenoside solution or 1 ml of ginsenoside monomer Rb1 solution, intramuscularly inject cows into the neck. Two weeks later, the same method was used to inject once more. After another 2 weeks, blood samples from cows were collected, blood lymphocytes were separated, and lymphocyte transformation tests were done. Calculate the leaching index. A high lymphatic index indicates a high cellular immune response.

[0019]

group

number of cows

Con A

PWM

golden yellow grapes

Coccal antigen

Inactivated Staphylococcus aureus vac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses an application of ginseng total saponin or monomer saponin Rb1 as vaccine immunologic adjuvant. The ginseng total saponin or monomer saponin Rb1 and aluminium hydroxide are mixed and used as vaccine immunologic adjuvant, and as compared with traditional aluminium hydroxide adjuvant said invention possesses the following advantages: (1) its side effect is less; (2) said vaccine can be stored under the condition of frozen low-temp. and it can prolong effective period of vaccine; (3) its method is simple and convenient, its quality is easy to be controlled; and (4) it can induce body to produce higher humoral immunity response.

Description

technical field [0001] The invention relates to the use of total ginsenosides or monomeric saponins Rb1 for preparing vaccine immune adjuvants. Background technique [0002] When vaccine adjuvants are used in combination with antigens, they can enhance the body's immune response to antigens, and are widely used in vaccine production. How to apply immune adjuvants to improve the effect of immunization is a hot spot in modern medical research. Since Glenny used aluminum hydroxide glue as an immune adjuvant in the 1920s, aluminum hydroxide adjuvant is still the only FDA-approved adjuvant that can be used in humans. But this type of adjuvant has many disadvantages, for example: 1) it mainly improves the humoral immune response, but has little effect on the cellular immune response; 2) because it increases the production of IgE antibodies, it is easy to cause allergic reactions; 3) the local irritation is relatively low. Big. (1，3) In recent years, var...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39
Inventor 胡松华
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap